Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70107 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Patricia D Maglalang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel H…. Hauptthemen laut MEDLINE: Oxcarbazepine, Models, Biological, Anticonvulsants, Pediatric Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Oxcarbazepine (OXC) is a second‐generation antiseizure medication, effective through its active metabolite, 10‐mono‐hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal‐onset and primary generalized tonic–clonic seizures, with recommended dosing based on age and body weight. This study uses physiologically based pharmacokinetic (PBPK) modeling and leverages pharmacokinetic (PK) data acquired from children enrolled in pragmatic trials to understand dosing and subsequent exposure requirements in children with obesity. Drug concentrations of OXC and MHD (n = 148 each) from children with (n = 31) and without (n = 10) obesity, aged 2‐20 years, were collected from two clinical trials (NCT01431326 and NCT02993861) and used for external evaluation of a previously developed PBPK model of OXC using PK‐Sim. We used a previously published virtual population that accounts for the obesity‐related changes in physiology (e.g., liver size and glomerular filtration rate) in children for PK simulations in children with obesity. Model evaluation showed that ≥80% of MHD concentrations contributed by about two thirds of study subjects (26 out of 41) fell within the 90% prediction interval. The PBPK model showed that children with obesity had lower median (interquartile range) simulated weight‐normalized clearance (0.060 L/h/kg [0.048‐0.076 L/h/kg]) than children without obesity (0.067 L/h/kg [0.060‐0.077 L/h/kg]). Simulations revealed that the recommended pediatric dosing regimen produced comparable MHD exposure between children with and without obesity at steady state, supporting its applicability regardless of obesity status. This PBPK‐based dosing aligns with product label recommendations and demonstrates the potential of PBPK modeling for dosing other drugs in children with obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Department of Pediatrics, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
- Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
- Duke Clinical Research Institute, Durham, NC, USA.
- Ann & Robert H. Lurie Children's Hospital of Chicago, IL, USA.
ORCID-Profile: Patricia D Maglalang, Jaydeep Sinha, Victόria Etges Helfer, Andrea Edginton, Kanecia Zimmerman, Chi Dang Hornik, William J Muller, Mobeen Rathore, Daniel K Benjamin, Jia-Yuh Chen, Ravinder Anand, Daniel Gonzalez
Förderung
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Maglalang, P. D., Sinha, J., Helfer, V. E., Edginton, A., Zimmerman, K., Hornik, C. D., Muller, W. J., Rathore, M., Benjamin, D. K., Chen, J. Y., Anand, R., Gonzalez, D., & Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee (2026). Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70107
Vancouver
Maglalang PD, Sinha J, Helfer VE, Edginton A, Zimmerman K, Hornik CD, et al. Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70107
BibTeX
@article{Maglalang2026,
author = {Maglalang, Patricia D and Sinha, Jaydeep and Helfer, Victόria Etges and Edginton, Andrea and Zimmerman, Kanecia and Hornik, Chi Dang and Muller, William J and Rathore, Mobeen and Benjamin, Daniel K and Chen, Jia-Yuh and Anand, Ravinder and Gonzalez, Daniel and Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee},
title = {Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70107}
}
EUVIMED